Clinical trial · Interventional
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma
NCT00577993CI-TRIAL-00048294completedPhase 3Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical research study is to compare chemotherapy given with rituximab to chemotherapy followed by rituximab. The safety of both treatment schedules will be studied. Laboratory tests of genetic changes in blood and bone marrow before and during the study will also be monitored.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (15)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ara-C | Drug | Cytarabine | ALIAS |
| Bleomycin | Drug | Bleomycin | ALIAS |
| Cisplatin | Drug | Cisplatin | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Decadron | Drug | Dexamethasone | ALIAS |
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| Fludarabine | Drug | Fludarabine | ALIAS |
| Interferon |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- 1: FND + Rituximab Followed by Interferon
- description
- Fludarabine/Novantrone/Decadron + Rituximab Followed by Interferon
- interventionNames
- Drug: Fludarabine
- Drug: Novantrone
- Drug: Decadron
- Drug: Rituximab
- Drug: Interferon
- type
- ACTIVE_COMPARATOR
- label
- 2: FND Followed by Interferon & Rituximab
- description
- Fludarabine/Novantrone/Decadron Followed by Interferon \& Rituximab
- interventionNames
- Drug: Fludarabine
- Drug: Novantrone
- Drug: Decadron
- Drug: Rituximab
- Drug: Interferon
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 76 Years
Show eligibility criteria text
Inclusion Criteria: 1. Previously untreated stage IV indolent B-cell lymphoma \[Amendment May 2001: eligibility restricted to follicular lymphoma\] 2. Age \<76 Exclusion Criteria: N/A
References
Publications (0)
Data not yet available
No reference posted for this study.